A Comprehensive Cross-Tabulation Analysis of Oral Carcinoma Patients: A Retrospective Study of Recent 7 Years.

Background and Objectives: According to the global cancer situation, which is very alarming, with over 10 million new diagnoses and more than 6 million deaths each year globally, cancer is one of the most prominent causes of morbidity and mortality today. One of the cancers is oral cancer. Oral cancer is the irregular development of malignant cells in the oral cavity. The study's objective was to decide the mortality of cross-tabulation among patients treated for oral carcinoma from Hospital Universiti Sains Malaysia (USM), Kelantan, Malaysia.
Materials and Methods: This chapter summarizes the medical history for 7 years from January 2011 to December 2018 of patients who have been treated for oral carcinoma in the Hospital USM, Oral and Maxillofacial Surgery (OMFS) Unit. Each patient's complete medical record was checked, and data gathered were based on age, gender, site lesion, clinical diagnosis, and mortality. Version 26.0 of the SPSS software was used to evaluate the correlation and distribution of patient survival.
Results: This was a retrospective cross-sectional review of the medical evidence of 117 patients infected for oral carcinoma at OMFS (Hospital USM). Sixty-seven (57.26%) of the patients were male and fifty (42.74%) were female. Patient age ranged from 25 to 93 years. Malay has the highest prevalence (85.5%) in oral carcinoma, followed by a second ethnic group, Chinese (7.7%). The result indicates that the majority of oral carcinoma patients were over 60 years old.Cases of oral squamous cell carcinoma have proved to be the most prevalent malignant tumour in the mouth cavity. The largest number of cases collected is 91% of the data collected. Mucoepidermoid carcinoma (10%) is the second most common small salivary gland tumor.
Conclusion: OSCC is the most prevalent kind of oral cancer. According to the data review, the most popular site for oral cancer is the tongue.
Competing Interests: There are no conflicts of interest.
(Copyright: © 2021 Journal of Pharmacy and Bioallied Sciences.)